Medicover Hospitals launches advanced TMS Lab in Navi Mumbai for psychiatric and neurological conditions

In August 2026, Medicover Hospitals, Navi Mumbai, launched its Advanced Transcranial Magnetic Stimulation (TMS) Laboratory, expanding access to non-invasive brain stimulation therapy for patients with selected psychiatric and neurological conditions.

The facility will offer evidence-based TMS protocols for conditions including treatment-resistant depression, obsessive-compulsive disorder (OCD), anxious depression, post-traumatic stress disorder (PTSD), smoking cessation, and migraine, along with selected neurological applications where scientific evidence is evolving. These also include stroke rehabilitation, post-stroke speech and language disorders, neuropathic pain, fibromyalgia, Parkinson’s disease, cerebellar ataxia, Alzheimer’s disease, and tinnitus.

The new facility will also help provide TMS for Major Depressive Disorder, Treatment-Resistant Depression, Obsessive-Compulsive Disorder, Anxious Depression, Post-Traumatic Stress Disorder, smoking cessation, and migraine, along with selected neurological applications such as stroke rehabilitation and post-stroke speech and language difficulties. Other neurological conditions, including neuropathic pain, fibromyalgia, Parkinson’s disease, cerebellar ataxia, Alzheimer’s disease and tinnitus, are also being considered for appropriate patients based on clinical assessment and available evidence.

For psychiatric conditions, TMS will also help provide an additional treatment option for patients who do not achieve adequate improvement with conventional approaches. The treatment is generally delivered through multiple sessions, with the number and frequency depending on the condition and selected protocol. 

Impact on the Healthcare Market

TMS uses controlled magnetic pulses to stimulate specific areas of the brain. The treatment is non-invasive and does not require surgery or general anesthesia. Depending on the condition and protocol, TMS can also be used to influence brain circuits involved in mood regulation, cognition, movement, pain processing, and other neurological functions. Patients undergo a detailed clinical assessment before treatment, and the protocol is selected according to the individual’s condition and treatment goals.

Every patient responds differently, which is why treatment should be individualized after a comprehensive assessment. At the TMS Lab, patients will receive evaluation, treatment planning, and follow-up under trained healthcare professionals. This multidisciplinary approach aims to ensure that TMS is integrated appropriately with medication, psychotherapy, and rehabilitation wherever required.

Impact on the Neurology Market

The global neurology market size was estimated at USD 3.88 billion in 2025 and is predicted to increase from USD 4.19 billion in 2026 to approximately USD 8.07 billion by 2035, expanding at a CAGR of 7.60% from 2026 to 2035.

According to Precedence Research, the collaboration among neurologists, neurosurgeons, and various specialists ensures a holistic and comprehensive approach to neurological disorders, fostering a more integrated and effective healthcare system. Continuous breakthroughs and neuroscience research drive ongoing innovation in treatments and diagnostic tools, elevating the standard of care. The market offers opportunities for companies and institutions to spearhead the development of novel treatments, meeting the unmet needs of patients and contributing to medical breakthroughs.

Advances in neuroscience and collaborative research initiatives are significantly contributing to the rising demand in the neurology market. The evolving understanding of the intricate workings of the nervous system, propelled by breakthroughs in imaging technologies and molecular biology, fuels the development of novel diagnostics and therapeutic interventions. These advancements, ranging from deciphering genetic markers to exploring intricate neural networks, pave the way for innovative treatment modalities.

Impact on the Cognitive Neuroscience Market

The global cognitive neuroscience market size was calculated at USD 41.44 billion in 2025 and is predicted to increase from USD 44.20 billion in 2026 to approximately USD 78.43 billion by 2035, expanding at a CAGR of 6.59% from 2026 to 2035.

According to Precedence Research, the market is driven by the advancements in brain imaging technologies, the rising prevalence of neurological disorders, and the growing demand for cognitive health research and therapies. Advanced technologies, including neuroimaging devices (fMRI, PET, EEG, MEG), brain monitoring devices, cognitive evaluation software, and computational modeling software, are also available in this market to enable further investigations of the processes of perception, memory, attention, decision-making, language processing, and consciousness.

The market is growing further due to increased government and private sector funding of neuroscience research. Significant projects, such as the Human Brain Project and BRAIN Initiative, are helping to provide the mechanisms for funding innovative tools, software, and research centers, and offer the possibility of developing and cultivating innovations in the field of brain functioning, cognition, and neurotherapeutics. Simultaneously, neuroimaging technologies, such as high-resolution fMRI, real-time EEG, and hybrid systems of PET-MRI, have transformed the process of brain mapping, allowing researchers to obtain a deeper picture of neural pathways and the processes of thinking.

Expert Opinion

Dr Suranjana Basak, Consultant Neurologist, said,

“The neurological applications of TMS are particularly relevant in rehabilitation, where recovery often requires repeated and specialized interventions. In selected patients following stroke, TMS may be used alongside physiotherapy, occupational therapy, and speech and language therapy. Similarly, research into TMS continues across conditions such as Parkinson’s disease, neuropathic pain, tinnitus, and other neurological disorders. The response can vary from patient to patient, making individual assessment and ongoing monitoring an important part of treatment.